-
Blood donation: dispelling a myth
Eligibility for blood donation in Canada is constantly evolving. For many years, the sexual partners of people with bleeding disorders were deferred from blood donation....
-
Return of Octostim spray delayed until late 2024
In a letter to the European Haemophilia Consortium dated May 31, 2022, Ferring Pharmaceuticals informed the bleeding disorder community that Octostim (desmopressin) Nasal Spray 1.5...
-
CBS supplier contracts for rFVIII and rFIX take effect April 4
March 30, 2022, Ottawa – Canadian Blood Services’ contracts with suppliers of recombinant factor VIII and IX for the 2022-2025 period take effect on April...
-
The 10 key takeaways from CHS advocacy efforts to obtain access to emicizumab (Hemlibra)
by David Page, CHS National Director of Health Policy The Canadian Hemophilia Society (CHS), its chapters and members have expended great efforts to advocate for...
-
Update on products in the pipeline
Updated charts for products in the pipeline have been uploaded on the CHS website. The CHS publishes four charts, one each for clotting factor concentrates, inhibitor...